^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Elyxyb (celecoxib)

    i
    Other names: DFN15, DFN-15, DFN-15A, DFN-15B
    Company:
    Collegium Pharma, Dr. Reddy’s, Sorrento
    Drug class:
    COX2 inhibitor
    Related drugs:
    14d
    Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=75, Completed, University of Southern California | Unknown status --> Completed
    Trial completion
    |
    Elyxyb (celecoxib) • celecoxib oral • patupilone (EPO 906)
    4ms
    RECON: Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer (clinicaltrials.gov)
    P2, N=39, Recruiting, Emory University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Elyxyb (celecoxib) • celecoxib oral
    8ms
    RECON: Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Emory University | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Elyxyb (celecoxib) • celecoxib oral
    9ms
    Celecoxib, Durvalaumab and Tremellimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Emory University
    New P2 trial
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Elyxyb (celecoxib) • celecoxib oral
    11ms
    Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population (clinicaltrials.gov)
    P2, N=25, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
    Enrollment open
    |
    erlotinib • methotrexate • Elyxyb (celecoxib) • celecoxib oral
    11ms
    Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Mayo Clinic | Initiation date: Jun 2025 --> Sep 2025
    Trial initiation date
    |
    erlotinib • methotrexate • Elyxyb (celecoxib) • celecoxib oral
    1year
    Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Mayo Clinic
    New P2 trial
    |
    erlotinib • methotrexate • Elyxyb (celecoxib) • celecoxib oral